Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Elevai Labs Inc ELAB

Elevai Labs, Inc. is a physician-dispensed skincare company. The Company conducts research and development to advance science-driven topical skincare that complements the medical aesthetics industry. It produces and commercializes topical skincare products that contain its proprietary stem cell derived Elevai Exosomes designed to enhance the appearance of skin. Its Precision Regenerative... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >

Current News (NDAQ:ELAB)

Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance

GlobeNewswire 7 hours ago

Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess

GlobeNewswire 9 hours ago

CORRECTION - Elevai Labs Inc.

GlobeNewswire 8 days ago

Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update

GlobeNewswire 8 days ago

Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange

GlobeNewswire November 4, 2024

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity

GlobeNewswire October 22, 2024

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity

GlobeNewswire October 21, 2024

Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock

GlobeNewswire October 4, 2024

REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations

GlobeNewswire October 3, 2024

Opinion & Analysis (NDAQ:ELAB)

No current opinion is available.

Bullboard Posts (NDAQ:ELAB)

Elevai Labs Inc.&#xA0;Announces Withdrawal of Offer to Excha

NEWS: $ELAB Elevai Labs Inc.&#xA0;Announces Withdrawal of Offer to Exchange and Plans to ReassessNEWPORT BEACH, Calif., Nov. 22...
whytestocks - 8 hours ago

CORRECTION - Elevai Labs Inc.

Just In: $ELAB CORRECTION - Elevai Labs Inc.NEWPORT BEACH, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- In a release&#xA0;earlier today...
whytestocks - 8 days ago